Healthcare business expanded from medical imaging to include biopharmaceuticals and regenerative medicine.

Valhalla, New York, July 12, 2017 – Global Fujifilm Healthcare executives reported on June 20th on the company’s diversified global healthcare business, which now generates an annual global revenue of $3.6 billion or nearly 17 percent of total company revenues* at a media briefing held in conjunction with the 2017 BIO International Convention in San Diego, California. Executives provided details on the company’s progress in two key areas: Contract Development and Manufacturing Organizations (CDMO) and regenerative medicine in the areas of iPS cells for therapeutics and life sciences.

“Healthcare is becoming one of the world’s most important and fast-growing industries and we expect treatments and drugs to do more than merely cure ailments,” said Akira Kase, Deputy General Manager, BIO CDMO Division, FUJIFILM Corporation. “We are looking for a higher quality of life overall. This is the democratization of healthcare globally and we are proud to bring the best possible technology to this mission.”

Fujifilm has evolved into a comprehensive healthcare company, offering products in the fields of, prevention, diagnostics and treatment. Founded in 1934, Fujifilm entered the X-ray film market in 1936 and went on to introduce the world’s first computed radiography system in 1983. Today the company continues to be a leader in diagnostic medical imaging and medical IT, and ​ ​now is also a world leader in cGMP CDMO supporting partners in the biopharmaceutical industry with the development and production of biology and vaccine candidates.

“Our commitment is to help our customers bring their therapies to patients through the application of good science, our knowledge and clinical process and our quality driven approach.” said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies.

Cellular Dynamics International (CDI), a FUJIFLM company reported on the company’s progress in regenerative medicine, including its continuing partnership with the California Institute for Regenerative Medicine (CIRM) and Coriell Institute for Health Sciences. This partnership resulted in the launch of the world’s largest publicly available diseased based stem cell bank with the shared goal of improving human health.

“Fujifilm is working closely with the entire Life Science community, using new and fundamentally enabling cell based technologies to bring CDI’s human differentiated induced pluripotent stem cell (iPSC) based products to the global life science tools and cellular therapeutics research communities,” said Kaz Hirao, President, Cellular Dynamics International, a FUJIFILM company. “Today, we are providing some of the world’s top scientists and engineers with disease specific cells to enable faster and surer progress toward disease research success. We believe that, in the future, these cells will be an integral part of the therapy and of the cure."

With its wide range of technologies and expansive vision, Fujifilm leverages the products, services, and hard-earned expertise that are rooted in the development of photographic products to enhance the quality of life of people worldwide.

For more information, please visit healthcaresolutions-us.fujifilm.com

* As of March 31, 2016 at an exchange rate of 112.54 yen to the dollar.

About Fujifilm
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2016, the company had global revenues of $22.1 billion, at an exchange rate of 112.54 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

About Fujifilm Healthcare
Fujifilm Healthcare is driving change and helping to shape the future of modern medicine across the care pathway of prevention, diagnosis and treatment. The company’s innovative solutions are derived from the depth of knowledge and core and fundamental technologies required for the complex design, engineering and manufacturing of photographic film. Fujifilm Healthcare is active in the fields of digital radiography, women's health, endoscopy, ultrasound, medical informatics, CDMO biopharmaceuticals, regenerative medicine and pharmaceuticals. As technology trailblazers, Fujifilm will continue to push boundaries and make breakthroughs with the overall mission of improving patient outcomes and changing lives. For more information, please visit: healthcaresolutions-us.fujifilm.com

About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization with locations in Billingham, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com.

About Cellular Dynamics International, a FUJIFILM company
Cellular Dynamics International, a FUJIFILM company, is a leading developer and supplier of human cells used in drug discovery, toxicity testing, and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, CDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company’s inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development. For more information please visit www.cellulardynamics.com.


All product and company names herein may be trademarks of their registered owners.

Lauren Geloso